Endo Pharmaceuticals Holdings News

's stock had its "neutral" rating reaffirmed by research analysts at Goldman Sachs in a report released on Wednesday.

The board of Human Genome Sciences is being sued by a shareholder, and the court is being petitioned to stop the company from using its "poison pill" to prevent the $2.6 billion hostile takeover attempt by GlaxoSmithKline .

Endo Health Solutions Inc. to Present at Jefferies and Co. 2012 Global Healthcare Conference A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/ . Click on Investor Relations, and then the link to the Event and Presentation.

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an agreement with Endo Pharmaceuticals Inc.

In trading on Friday, shares of Endo Health Solutions Inc crossed above their 200 day moving average of $33.67, changing hands as high as $33.69 per share.

CHADDS FORD, Pa., May 23, 2012 /PRNewswire-FirstCall/ -- Shareholders of Endo Pharmaceuticals Holdings Inc.

RALEIGH, N.C., May 10, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc.

There's no question that Teva Pharmaceuticals rewarded long-term investors with years and years of growth as it became the world's largest generic drug manufacturer.

A U.S. Senate panel has launched a probe of possible links between three drugmakers and nonprofit medical groups that advocated for increasing the use of prescription painkillers, now the target of a nationwide law enforcement crackdown.

's stock had its "neutral" rating reaffirmed by Zacks in a report released on Friday.

CHADDS FORD, Pa., May 4, 2012 /PRNewswire/ -- Endo today announced that Alan Levin, executive vice president and chief financial officer, will present a corporate overview at the Bank of America Merrill Lynch 2012 Heath Care Conference on Wednesday, May 16, 2012 at 12:20 p.m. ET.

Several other analysts have also recently commented on the stock. Analysts at Citigroup set a $48.00 price target on shares of Endo Pharmaceuticals in a research note to investors on Monday, March 26th.

I'd now like to turn the call over to Mr. Blaine Davis, Senior Vice President of Corporate Affairs.

Endo Pharmaceuticals Holdings Inc. Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA ER And Voltaren Gel , increased 23 percent versus prior year; Driven by full quarter addition of AMS as well as Qualitest revenue growth of 8 percent.